• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ALA
Click for more information
2.70% 18.0¢

AROVELLA THERAPEUTICS LIMITED - Charts / Financials

Market Cap $168.2M  ! watchlist Created with Sketch. Add to my watchlist

Arovella Therapeutics Limited is a biotechnology company. The Company is focused on... Arovella Therapeutics Limited is a biotechnology company. The Company is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. The Company's lead product is ALA-101. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. ALA-101 is a next-generation CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukemias. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. The Company is also engaged in expanding solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Its iNKT cells also contain an invariant T cell receptor (iTCR) that targets alpha-galactosylceramide (a-GalCer) bound CD1d, another antigen found on the surface of several cancer types.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 15.32pm 21/11/2024 (20 minute delay) ?
Day
Open 19.0¢   Day High 19.5¢   Day Low 18.0¢
Daily Volume 436801
Bids   Sellers
Number Price Volume   Number Price Volume
11 18.0¢ 534346   6 18.5¢ 183527

Directors & Senior Management

Mr. Michael Baker Chief Executive Officer, Managing Director, Director
Mr. Tim Luscombe Chief Financial Officer, Company Secretary
Dr. Nicole van Der Weerden Chief Operating Officer
Dr. Thomas Duthy Non-Executive Chairman of the Board
Dr. Elizabeth Stoner Non-Executive Director
Dr. Debora Barton Non-Executive Independent Director
Mr. Gary Jonathan Phillips Independent Non-Executive Director

Data source: Refinitiv

(20min delay)
Last
18.0¢ 		Change
-0.005(2.70%) 		Mkt cap ! $168.2M
Open High Low Value Volume
19.0¢ 19.5¢ 18.0¢ $81.53K 436.8K

Buyers (Bids)

No. Vol. Price($)
11 534346 18.0¢
 

Sellers (Offers)

Price($) Vol. No.
18.5¢ 183527 6
View Market Depth
Last trade - 16.10pm 21/11/2024 (20 minute delay) ?
Last
18.5¢ 		  Change
-0.005 ( 1.49 %)
Open High Low Volume
18.8¢ 19.0¢ 18.0¢ 224693
Last updated 15.32pm 21/11/2024 ?

Top Stories

Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech

Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.